# OnCo record infinity-pharmaceuticals (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/infinity-pharmaceuticals/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "infinity-pharmaceuticals" ;
  schema:name "Infinity Pharmaceuticals"@en ;
  schema:alternateName "Infinity Pharmaceuticals, Inc."@en, "Infinity"@en ;
  schema:description "Infinity was the Cambridge biotech that discovered duvelisib, the PI3K-delta/gamma inhibitor later approved for chronic lymphocytic leukaemia, before licensing it out and turning to eganelisib; it filed for bankruptcy in 2023."@en ;
  schema:url <https://onco.cc/companies/infinity-pharmaceuticals/>, <http://www.infi.com> ;
  schema:dateModified "2026-09-11"^^xsd:date ;
  schema:citation <http://www.infi.com>, <https://clinicaltrials.gov/search?lead=Infinity%20Pharmaceuticals%2C%20Inc.>, <https://www.wikidata.org/wiki/Q30296176> ;
  onco:tag "ctgov-sponsor" ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/cll/> ;
  onco:drugs <https://onco.cc/drugs/duvelisib/> ;
  onco:terms <https://onco.cc/terms/pivotal-trial/>, <https://onco.cc/terms/clinical-trial/> .